MX2017014768A - Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. - Google Patents

Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Info

Publication number
MX2017014768A
MX2017014768A MX2017014768A MX2017014768A MX2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A MX 2017014768 A MX2017014768 A MX 2017014768A
Authority
MX
Mexico
Prior art keywords
methods
progestin
shbg
side effects
modulation
Prior art date
Application number
MX2017014768A
Other languages
English (en)
Inventor
Macfarlane Katie
E Kafrissen Michael
Kydonieus Agis
Original Assignee
Agile Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agile Therapeutics Inc filed Critical Agile Therapeutics Inc
Publication of MX2017014768A publication Critical patent/MX2017014768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se divulgan composiciones y métodos para la administración de hormonas progestina que tienen afinidad de unión por la globulina de unión a la hormona sexual (SHBG). Las composiciones combinan dichas progestinas con ligandos de SHBG no de progestina para desplazar al menos parte de la progestina de la SHBG en el plasma sanguíneo, aumentando de esta forma su biodisponibilidad. También se divulgan métodos para modular los niveles de progestina y estrógenos e la sangre mediante el uso de la unión a SHBG y desplazamiento, para optimizar la eficacia de formulaciones anticonceptivas y minimizar los efectos secundarios y los eventos adversos.
MX2017014768A 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios. MX2017014768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163113P 2015-05-18 2015-05-18
US201562254999P 2015-11-13 2015-11-13
PCT/US2016/033024 WO2016187269A1 (en) 2015-05-18 2016-05-18 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Publications (1)

Publication Number Publication Date
MX2017014768A true MX2017014768A (es) 2018-03-23

Family

ID=56116539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014768A MX2017014768A (es) 2015-05-18 2016-05-18 Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.

Country Status (10)

Country Link
US (1) US20180125860A1 (es)
EP (1) EP3297634A1 (es)
JP (2) JP2018515552A (es)
CN (1) CN107995864A (es)
AU (2) AU2016264137B2 (es)
BR (1) BR112017024783A2 (es)
CA (1) CA2986039A1 (es)
HK (1) HK1251938A1 (es)
MX (1) MX2017014768A (es)
WO (1) WO2016187269A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
WO2016203011A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible dosage unit containing an estetrol component
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
RS61812B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetriol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JP2020511463A (ja) * 2017-03-15 2020-04-16 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 個別化避妊製剤
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) * 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
PL181582B1 (pl) 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7214381B2 (en) 2000-08-03 2007-05-08 Antares Pharma Ipl Ag Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
NZ548091A (en) * 2003-12-12 2009-12-24 Bayer Schering Pharma Ag Transdermal delivery system of hormones without penetration enhancers
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
US20100178323A1 (en) * 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
AU2008318284B2 (en) 2007-11-02 2012-03-22 Acrux Dds Pty Ltd Transdermal delivery system
US9198876B2 (en) * 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2740004A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) * 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198920B2 (en) * 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2861324A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal hormone delivery
CA2894696A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents

Also Published As

Publication number Publication date
CA2986039A1 (en) 2016-11-24
HK1251938A1 (zh) 2019-05-03
EP3297634A1 (en) 2018-03-28
WO2016187269A1 (en) 2016-11-24
US20180125860A1 (en) 2018-05-10
JP2018515552A (ja) 2018-06-14
AU2021262853A1 (en) 2021-12-02
AU2016264137B2 (en) 2021-08-19
AU2016264137A1 (en) 2018-01-18
BR112017024783A2 (pt) 2018-08-07
JP2021169503A (ja) 2021-10-28
CN107995864A (zh) 2018-05-04

Similar Documents

Publication Publication Date Title
MX2017014768A (es) Composiciones anticonceptivas y metodos para mejorar la eficacia y modulacion de los efectos secundarios.
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2020000333A (es) Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
MX2018011705A (es) Composicion farmaceutica de hormona esteroide.
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015017655A (es) Modulador de receptores de estrogeno y uso del mismo.
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2016014281A (es) Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020002527A (es) Compuestos de complejo de hierro para uso terapeutico.
EA201792595A1 (ru) Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
MX2019001321A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
MX2021006102A (es) Suministro mejorado de agentes grandes.
MX2019007176A (es) Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos.
MX2017013879A (es) Composiciones que comprenden anakinra.
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases